FDMT 4D Molecular Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1650648 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY79,952.5%
TTM net income YoY4.2%
TTM EPS YoY28.0%
Revenue 3-yr CAGR63.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-226.0%
Net margin-208.6%
FCF margin—
EBITDA margin-220.9%
Returns
ROE-56.7%
ROA-47.0%
ROIC (approx.)-53.7%
Asset turnover0.23x
Leverage & solvency
Liabilities / assets21.2%
Debt / equity0.06x
Current ratio6.15x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.14M | $3.78M | $3.05M | $85.09M | $90,000 | $15,000 | $14,000 | $1,000 |
| R&D expense | $69.78M | $68.28M | $64.98M | $57.61M | $49.44M | $47.95M | $40.70M | $43.09M |
| SG&A expense | $15.59M | $12.52M | $11.69M | $12.77M | $11.84M | $11.52M | $12.94M | $13.03M |
| Operating income | -$81.22M | -$77.03M | -$73.62M | $14.71M | -$61.19M | -$59.46M | -$53.62M | -$56.12M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$78.06M | -$72.94M | -$68.76M | $19.40M | -$56.88M | -$54.66M | -$47.97M | -$49.67M |
| EBITDA | -$80.02M | -$75.72M | -$72.35M | $15.93M | -$59.88M | -$58.16M | -$52.57M | -$55.02M |
| EPS (basic) | -1.08 | -1.04 | -1.01 | — | -1.01 | -0.98 | -0.86 | — |
| EPS (diluted) | -1.08 | -1.04 | -1.01 | — | -1.01 | -0.98 | -0.86 | — |
| Weighted avg. shares (diluted) | 72.25M | 70.27M | 68.06M | — | 56.13M | 55.93M | 55.74M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $39.10M | $70.37M | $72.49M | $60.24M | $48.55M | $77.16M | $133.53M | $149.34M |
| Short-term investments | $267.88M | $290.96M | $318.40M | $342.41M | $256.51M | $216.07M | $187.91M | $275.54M |
| Current assets | $322.29M | $382.96M | $405.36M | $413.13M | $312.38M | $303.29M | $332.57M | $434.93M |
| PP&E, net | $11.22M | $12.38M | $13.59M | $14.87M | $16.15M | $17.50M | $18.75M | $19.53M |
| Total assets | $428.75M | $492.62M | $512.90M | $566.71M | $423.98M | $473.64M | $515.73M | $560.38M |
| Current liabilities | $52.39M | $47.67M | $43.40M | $43.98M | $37.11M | $34.68M | $26.90M | $29.15M |
| Long-term debt | $19.68M | $19.59M | — | $0 | — | — | — | — |
| Total debt | $19.68M | $19.59M | — | $0 | — | — | — | — |
| Total liabilities | $90.81M | $84.96M | $61.07M | $61.05M | $55.00M | $52.75M | $46.01M | $49.78M |
| Shareholders' equity | $337.94M | $407.66M | $451.84M | $505.66M | $368.98M | $420.89M | $469.72M | $510.61M |
| Net debt | -$19.43M | -$50.78M | — | -$60.24M | — | — | — | — |
| Shares outstanding | 56.37M | 55.21M | 52.27M | 57.61M | 46.77M | 46.70M | 46.32M | 45.79M |
| Cash flow statement | ||||||||
| Operating cash flow | -$56.71M | -$70.00M | -$68.12M | $28.55M | -$46.50M | -$43.38M | -$47.76M | -$45.86M |
| Capital expenditure | $49,000 | — | — | -$70,000 | -$91,000 | $66,000 | $631,000 | $949,000 |
| Free cash flow | -$56.76M | — | — | $28.62M | -$46.41M | -$43.44M | -$48.39M | -$46.81M |
| Investing cash flow | $24.84M | $25.54M | $68.89M | -$128.85M | $17.78M | -$13.85M | $31.95M | $7.06M |
| Financing cash flow | $604,000 | $42.34M | $11.48M | $111.98M | $116,000 | $862,000 | $0 | $601,000 |
| Depreciation & amortization | $1.20M | $1.30M | $1.27M | $1.22M | $1.30M | $1.30M | $1.05M | $1.10M |
| Stock-based compensation | $8.26M | $5.88M | $4.45M | $5.55M | $4.52M | $4.96M | $6.99M | $7.58M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.